Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model
-
Published:2021-03-19
Issue:11
Volume:124
Page:1809-1819
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Jiang Yanyan, Martin Jennifer, Alkadhimi Maryam, Shigemori Kay, Kinchesh Paul, Gilchrist Stuart, Kersemans VeerleORCID, Smart Sean, Thompson James M., Hill Mark A., O’Connor Mark J., Davies Barry R.ORCID, Ryan Anderson J.ORCID
Abstract
Abstract
Background
The radiosensitising effect of the poly(ADP-ribose) polymerase inhibitor olaparib on tumours has been reported. However, its effect on normal tissues in combination with radiation has not been well studied. Herein, we investigated the therapeutic index of olaparib combined with hemithoracic radiation in a urethane-induced mouse lung cancer model.
Methods
To assess tolerability, A/J mice were treated with olaparib plus whole thorax radiation (13 Gy), body weight changes were monitored and normal tissue effects were assessed by histology. In anti-tumour (intervention) studies, A/J mice were injected with urethane to induce lung tumours, and were then treated with olaparib alone, left thorax radiation alone or the combination of olaparib plus left thorax radiation at 8 weeks (early intervention) or 18 weeks (late intervention) after urethane injection. Anti-tumour efficacy and normal tissue effects were assessed by visual inspection, magnetic resonance imaging and histology.
Results
Enhanced body weight loss and oesophageal toxicity were observed when olaparib was combined with whole thorax but not hemithorax radiation. In both the early and late intervention studies, olaparib increased the anti-tumour effects of hemithoracic irradiation without increasing lung toxicity.
Conclusions
The addition of olaparib increased the therapeutic index of hemithoracic radiation in a mouse model of lung cancer.
Funder
RCUK | Medical Research Council
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference47 articles.
1. Murai, J., Huang, S. Y., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H. et al. Trapping of PARP1 and PARP2 by clinical PARP Inhibitors. Cancer Res. 72, 5588–5599 (2012). 2. Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852–861 (2011). 3. Laird, J. H., Lok, B. H., Ma, J., Bell, A., de Stanchina, E., Poirier, J. T. et al. Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts. Clin. Cancer Res. 24, 5143–5152 (2018). 4. Wang, L., Mason, K. A., Ang, K. K., Buchholz, T., Valdecanas, D., Mathur, A. et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest. N. Drugs 30, 2113–2120 (2012). 5. Senra, J. M., Telfer, B. A., Cherry, K. E., McCrudden, C. M., Hirst, D. G., O’Connor, M. J. et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol. Cancer Ther. 10, 1949–1958 (2011).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|